"More and more patients are surviving end-stage heart failure thanks to durable, implantable heart pumps, known as LVADs," said Gerin Rachel Stevens, MD, an author of the study and director of cardiomyopathy at Northwell Health, medical director of cardiomyopathy and cardiac transplantation at North Shore University Hospital and a Feinstein Institute scientist. "For those patients ineligible for heart transplantation, 'destination' or long-term LVADs improve both survival and quality of life, but it is important to understand how these devices impact the kidney. By understanding the risk factors for kidney injury, we can better evaluate LVAD candidates and put measures in place both before and after the device is implanted to help maintain the patient's health."
‘LVAD, a temporary therapy for patients with congestive heart failure awaiting heart transplants has potential risk of kidney dysfunction.’
What researchers identified were a host steps, which when used in concert, could result in LVAD patients who enjoy improved outcomes.
Some of the interventions posed in the study include having a nephrologist on the medical team pre-implantation, enhanced training for dialysis nurses in the function of LAVD's and identifying patients with chronic kidney disease prior to transplant.
"Knowledge of cardiac devices and their interaction with the kidney is going to be of paramount importance for practicing nephrologists around the world," said Daniel W. Ross, MD, lead author and assistant professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, attending nephrologist for Northwell Health and Feinstein Institute scientist. "We hope this article serves as a reference for all renal physicians involved in the care of a cardiac patient with heart failure and spark ideas for future research."
Source: Eurekalert
